Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
The roadmap makes it easier for Cincinnati residents to follow their plan with confidence
Wegovy is a prescription medicine used for chronic weight management in eligible patients
Las dosis normalmente recomendadas de tirzepatida para adultos incluyen: El aumento de las dosis de tirzepatida debe ser realizado bajo orientacin del endocrinlogo, con incrementos de 2,5 mg, luego de 4 semanas como mnimo con la misma dosis, de acuerdo con la respuesta al tratamiento, la tolerancia a este medicamento y el surgimiento de efectos secundarios
From 2.4% to 17.6% in Four Years A Truveta analysis of real-world data from January 2021 to September 2025 found that semaglutide or tirzepatide prescribing among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025 more than a seven-fold increase
General PA criteria include: BMI threshold: BMI 30 (obesity), or BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease) Documentation of medical necessity: Clinical notes confirming obesity diagnosis, comorbidities, and treatment rationale from a licensed provider Prior lifestyle program participation: Many plans require documentation of participation in a structured diet and exercise program for a defined period (typically 36 months) before GLP-1 medications are authorized Non-diabetic indication: For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide weight loss dose), the weight management indication must be documented separately from diabetes management Step therapy: Some Cigna plans may require an oral agent (such as phentermine or Contrave) trial before authorizing higher-cost GLP-1 medications Ongoing authorization: GLP-1 PA approvals are typically renewable annually and may require documentation of 5% body weight reduction to continue coverage Klarity Healths clinical team may assist with the prior authorization process
Zhao, The effects of advanced glycation end-products on skin and potential anti-glycation strategies
